

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5109196

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
ARALEZ PHARMACEUTICAL TRADING DAC	08/10/2018
RECEIVING PARTY DATA	
Name:	DEERFIELD MANAGEMENT COMPANY, L.P., AS ADMINISTRATIVE AGENT
Street Address:	780 THIRD AVENUE, 37TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10017
PROPERTY NUMBERS Total: 23	
Property Type	Number
Patent Number:	6645987
Patent Number:	7304078
Patent Number:	6894065
Patent Number:	7488742
Patent Number:	7235567
Patent Number:	7541471
Patent Number:	7605275
Patent Number:	7626045
Patent Number:	7772276
Patent Number:	7989653
Patent Number:	8138180
Patent Number:	8258319
Patent Number:	8273790
Patent Number:	8618314
Patent Number:	7713999
Patent Number:	7687631
Patent Number:	8329905
Patent Number:	8575351
Patent Number:	9604971
Patent Number:	7569612

PATENT

Property Type	Number
Patent Number:	7741373
Patent Number:	7741374
Patent Number:	7915247

CORRESPONDENCE DATA

Fax Number:
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3125778467
Email: rebecca.paul@kattenlaw.com
Correspondent Name: REBECCA A. PAUL C/O KATTEN MUCHIN ROSENMAN LLP
Address Line 1: 525 WEST MONROE STREET
Address Line 4: CHICAGO, ILLINOIS 60661

NAME OF SUBMITTER:	REBECCA A. PAUL
SIGNATURE:	/Rebecca A. Paul/
DATE SIGNED:	08/24/2018

Total Attachments: 6
source=Deerfield Aralez PSA#page1.tif
source=Deerfield Aralez PSA#page2.tif
source=Deerfield Aralez PSA#page3.tif
source=Deerfield Aralez PSA#page4.tif
source=Deerfield Aralez PSA#page5.tif
source=Deerfield Aralez PSA#page6.tif

NOTICE
OF
GRANT OF SECURITY INTEREST
IN
PATENTS

United States Patent and Trademark Office

Ladies and Gentlemen:


Please be advised that pursuant to the Super-Priority Debtor-in-Possession Security and Pledge Agreement dated as of August 10, 2018 (as the same may be amended, modified, extended or restated from time to time, the "Agreement") by and among the Obligor party thereto (each an "Obligor" and collectively, the "Obligors") and Deerfield Management Company, L.P., a Delaware limited partnership, as administrative agent (in such capacity, together with its successors and assigns in such capacity, the "Administrative Agent") for the Secured Parties, the undersigned Obligor has granted a continuing security interest in, and a right to set off against, any and all right, title and interest of such Obligor in and to the patents and patent applications set forth on Schedule 1 hereto to the Administrative Agent for the Secured Parties. Capitalized terms used herein without definition shall have the meanings assigned to them in the Agreement, or if not defined therein, in the Credit Agreement (as defined in the Agreement).

The undersigned Obligor and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the foregoing patents and patent applications (i) may only be terminated in accordance with the terms of the Agreement and (ii) is not to be construed as an assignment of any patent or patent application.

Very truly yours,

ARALEZ PHAMACEUTICALS TRADING

DESIGNATED ACTIVITY COMPANY

By: 

Name: Andrew I. Koven

Title: Director

Acknowledged and Accepted:

DEERFIELD MANAGEMENT COMPANY, L.P.,
as Administrative Agent

By: Flynn Management, LLC, its General Partner

By: _____


Name: David Clark

Title: Authorized Signatory

Acknowledged and Accepted:

DEERFIELD MANAGEMENT COMPANY, L.P.,
as Administrative Agent

By: Flynn Management, LLC, its General Partner

By: 

Name: David Clark

Title: Authorized Signatory

SCHEDULE I**Aralez DAC****Patents:**

Loan Party	Product	Title	Status	Application	Filing Date	Patent	Grant Date
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	THROMBIN RECEPTOR ANTAGONISTS	Issued	09/880,222	13-Jun-01	6,645,987	11-Nov-03
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	Thrombin receptor antagonists	Issued	10/412,982	14-Apr-03	7,304,078	4-Dec-07
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	THROMBIN RECEPTOR ANTAGONISTS	Issued	10/457,256	9-Jun-03	6,894,065	17-May-05
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	Thrombin receptor antagonists	Issued	10/671,216	25-Sep-03	7,488,742	10-Feb-09
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist	Issued	10/755,066	9-Jan-04	7,235,567	26-Jun-07
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	Synthesis of himbacine analogs	Issued	11/330,935	12-Jan-06	7,541,471	2-Jun-09
ARALEZ PHARMACEUTIC	ZONTIVITY	EXO- AND DIASTEREO- SELECTIVE SYNTHESSES OF HIMBACINE ANALOGS	Issued	11/331,324	12-Jan-06	7,605,275	20-Oct-09

134983723v1

Loan Party	Product	Title	Status	Application	Filing Date	Patent	Grant Date
ALS TRADING DAC							
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	Synthesis of himbacine analogs	Issued	12/428,773	23-Apr-09	7,626,045	1-Dec-09
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	Exo-selective synthesis of himbacine analogs	Issued	11/330,521	12-Jan-06	7,772,276	10-Aug-10
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	EXO- AND DIASTEREO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS	Issued	12/505,079	17-Jul-09	7,989,653	2-Aug-11
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS	Issued	12/827,000	30-Jun-10	8,138,180	20-Mar-12
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	EXO- AND DIASTEREO- SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS	Issued	13/168,029	24-Jun-11	8,258,319	4-Sep-12
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	EXO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS	Issued	13/370,768	10-Feb-12	8,273,790	25-Sep-12
ARALEZ PHARMACEUTIC ALS TRADING DAC	ZONTIVITY	EXO- AND DIASTEREO-SELECTIVE SYNTHESIS OF HIMBACINE ANALOGS	Issued	13/563,136	31-Jul-12	8,618,314	31-Dec-13

134983723v1

Loan Party	Product	Title	Status	Application	Filing Date	Patent	Grant Date
ARALEZ PHARMACEUTICALS TRADING DAC	ZONTIVITY	Thrombin receptor antagonists	Issued	11/733,635	10-Apr-07	7,713,999	11-May-10
ARALEZ PHARMACEUTICALS TRADING DAC	ZONTIVITY	Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2-yl]methyl}phosphonate	Issued	11/824,245	29-Jun-07	7,687,631	30-Mar-10
ARALEZ PHARMACEUTICALS TRADING DAC	ZONTIVITY	SYNTHESIS OF DIETHYL{[5-(3-FLUOROPHENYL)-PYRIDINE-2-YL]METHYL}PHOSPHONATE	Issued	12/701,174	5-Feb-10	8,329,905	11-Dec-12
ARALEZ PHARMACEUTICALS TRADING DAC	ZONTIVITY	ACTIVE METABOLITE OF A THROMBIN RECEPTOR ANTAGONIST	Issued	13/376,093	19-Apr-12	8,575,351	5-Nov-13
ARALEZ PHARMACEUTICALS TRADING DAC	ZONTIVITY	CO-CRYSTAL OF THE PAR-1 RECEPTOR ANTAGONISTS VORAPAXAR AND ASPIRIN	Issued	14/905,193	14-Jan-16	9,604,971	28-Mar-17
ARALEZ PHARMACEUTICALS TRADING DAC	FIBRICOR	Methods of use of fenofibric acid	Issued	12/141,377	16-Jun-08	7,569,612	4-Aug-09
ARALEZ PHARMACEUTICALS TRADING DAC	FIBRICOR	Methods of use of fenofibric acid	Issued	12/501,678	13-Jul-09	7,741,373	22-Jun-10
ARALEZ PHARMACEUTICALS TRADING DAC	FIBRICOR	METHODS OF USE OF FENOFIBRIC ACID	Issued	12/556,644	10-Sep-09	7,741,374	22-Jun-10

134983723v1

Loan Party	Product	Title	Status	Application	Filing Date	Patent	Grant Date
ARALEZ PHARMECEUTIC ALS TRADING DAC	FIBRICOR	Methods of use of fenofibric acid	Issued	12/141,280	18-Jun-08	7,915,247	29-Mar-11